Sangamo Therapeutics Inc
NASDAQ:SGMO 4:00:00 PM EDT
| Market Cap (Intraday) | 105.46M |
| Current PE | N/A |
| Forward PE | N/A |
| 2yr Forward PE | N/A |
| 10-Day MA | $0.52 |
| 50-Day MA | $0.78 |
| 200-Day MA | $0.71 |
Sangamo Therapeutics Inc Stock, NASDAQ:SGMO
501 Canal Boulevard, 501 Canal Boulevard, Richmond, California 94084
United States of America
Phone: +1.510.970.6000
Number of Employees: 405
Description
Sangamo Therapeutics, Inc. is a clinical stage biotechnology company, which engages in the research and development of zinc finger proteins. It focuses on three therapeutic areas: inherited metabolic diseases, central nervous system, and diseases and immunology, which consist of inflammatory and autoimmune diseases. It also offers complementary technology platforms such as gene therapy, ex vivo cell therapy, in vivo genome editing, and in vivo genome regulation. The company was founded by Edward O. Lanphier II in 1995 and is headquartered in Richmond, CA.